Illumina, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Illumina, Inc. trades at $190.91 (market cap $29.12B), while ProShares UltraPro Short QQQ ETF trades at $37.23. The key difference: Illumina, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | SQQQ | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $205.10 | $92.95 |
52-Week Low | $91.00 | $36.31 |
Enterprise Value | $30.48B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
SQQQ trades at $37.05, down 1.83% on the day, reflecting its inverse leveraged structure designed to move opposite the Nasdaq-100. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold conditions suggest potential for short-term bounces. Recent news highlights SQQQ's role as a tactical hedging tool rather than a long-term investment, with significant erosion risk due to daily reset mechanisms.
SQQQ serves as a high-risk tactical instrument for bearish Nasdaq-100 bets, with success dependent on precise market timing. The ETF faces structural decay from daily rebalancing, making it unsuitable for buy-and-hold strategies. Current market volatility and tech sector concerns create potential short-term opportunities, but long-term holders have historically suffered substantial losses.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →